Brattea, A Leading Renal Denervation Company In China, Completes Over $Us20 Million Series B+ Financing, Led By Kuanping Capital

Brattea, a leading renal denervation (RDN) medical technology company in China, announced today its successful completion of over $US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital. New investors include Hengxu Capital, Pudong Science & Technology Co. and Brosmed. Prior round investors include Northern Light Venture Capital, BioTrack Capital, and Sherpa Healthcare Partners.